ClinicalTrials.gg
RecruitingNCT05819463Updated Nov 17, 2026

Treatment and Medical Care of Patients With Moderate-to-severe Atopic Dermatitis - TREATswitzerland

An observational study in Atopic Dermatitis, sponsored by Swiss Society of Dermatology and Venereology. Recruiting at 10 sites in Switzerland. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Swiss Society of Dermatology and Venereology · Observational

From the registry’s dates

  • Started Jun 2022; still recruiting 4 years 5 months later.
Updated Nov 17, 2026Eligibility revised4 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
700
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies in Dermatitis, Atopic with a site in Switzerland — 3 open to participants now, 5 under way, none of them phase 3. Dermatitis, Atopic · Switzerland.

Started
2022
with 3 others
Observational
6 of 31
3 open now
Registered
25th of 31
by date

Among the 31 studies in Dermatitis, Atopic with a site in Switzerland, this one is one of 4 that started in 2022, is one of 6 observational ones, and was the 25th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

3 of the 31 studies in Dermatitis, Atopic with a site in Switzerland are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Dermatitis, Atopic with a site in Switzerland, or all of them as a file.
02

Study summary

As structured and detailed data on the management of AD, a common chronic inflammatory skin disease which has a high impact on patients' quality of life and socioeconomic burden, are not available in Switzerland, the planned registry will overcome this gap. It will provide data on the medical care of patients with AD for health care research and allow to study the efficacy and safety of approved and available therapies for AD in daily life.

Read the detailed description

A prospective, non-interventional, national multicenter study in patients with moderate-to-severe AD. According to the availability of approved systemic drugs for the treatment of AD, the study will include children ≥12 years, adolescents and adult patients.

The general goal of the AD registry TREATswitzerland is to provide the scientific community with a disease-oriented prospective cohort of patients suffering from moderate-to-severe AD.

The primary objective of the AD registry is the documentation of medical care given to patients with moderate-to-severe AD in order to assess the appropriateness of care.

Further objectives of the AD registry are:

  1. to evaluate the psychosocial impact of AD;
  2. to provide up-to-date epidemiologic data that allow investigating risk factors for favorable or unfavorable disease courses and comorbidities; and
  3. to establish a research network and foster clinical research projects.

The study procedures include:

  • No study related intervention will be performed
  • Patients have to fulfill all inclusion criteria to be enrolled in the study.
  • Included patients are prospectively followed for at least 24 months. A maximum duration of follow-up is not intended.
  • During the observation period, standardized study visits are performed to prospectively document patient characteristics, clinical data, patient-reported outcomes, reasons for treatment decisions, and satisfaction with treatment.
03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

The criteria were revised on the registry on Nov 17, 2026. See what changed

Ages eligible
12 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

The study aims at including 700 patients with moderate to severe atopic dermatitis in the registry.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 12 years
  • AD according to the UK Working Party's Diagnostic Criteria (28)
  • Moderate to severe AD as defined by
  • objective SCORAD > 20 or IGA ≥ 3 (moderate) or
  • currently on systemic antiinflammatory therapy for AD or
  • previous systemic antiinflammatory therapy for AD within past 24 months
  • current or anti-inflammatory topical therapy with JAK inhibitors

Exclusion criteria

Exclusion Criteria:

  • refusal to sign the form
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
700 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Evaluation of the type of systemic therapy used in patients with moderate-to-severe atopic dermatitis

    assess medical substances given systemically to treat AD

    Time frame: 24 months

Secondary outcomes

  1. assessment of patients demographic data

    assess sex (male, female), age (years)

    Time frame: 24 months

  2. assessment of past treatment and current treatment

    assess specific medical substances (name, dosage, duration of therapy, clinical effects, adverse effects)

    Time frame: 24 months

  3. assessment of concomitant topical therapy for AD and concomitant treatment

    describe medical substances given for AD skin therapy (e.g. topical corticosteroids) and topical calcineurin inhibitors), and medical substances given for concomitant diseases

    Time frame: 24 months

  4. assessment of past and current comorbidities

    describe diseases

    Time frame: 24 months

  5. change in subjective and objective SCORAD (SCORing Atopic Dermatitis)

    outcome measure for disease severity

    Time frame: 24 months

  6. change in EASI (Eczema Area and Severity Index)

    Investigator-assessed outcome measure for disease severity

    Time frame: 24 months

  7. change in DLQI (Dermatology Life Quality Index)

    Patient-reported outcome measure for skin-related quality of life

    Time frame: 24 months

  8. change in POEM (Patient Oriented Eczema Measure)

    Patient-reported outcome measure for atopic eczema severity

    Time frame: 24 months

  9. change in RECAP (Recap of atopic eczema)

    Patient-reported outcome measure to capture eczema control

    Time frame: 24 months

07

Study locations

9 of 10 sites recruiting
  • Universitätsspital Basel, Allergologie
    Basel, 4031, Switzerland
    Recruiting
  • Inselspital, Department of Dermatology
    Bern, 3010, Switzerland
    Recruiting
  • Dermatology & Skin Care Clinic
    Buochs, 6374, Switzerland
    Recruiting
  • HFR Hôpital Cantonal de Fribourg
    Fribourg, 1752, Switzerland
    Recruiting
  • Dermatologie et vénéréologie, Hôpitaux Universitaires de Genève (HUG)
    Geneva, 1205, Switzerland
    Recruiting
  • Dermatologie CHUV
    Lausanne, 1011, Switzerland
    Recruiting
  • Luzerner Kantonsspital, Zentrum für Dermatologie und Allergologie
    Lucerne, 6000, Switzerland
    Not yet recruiting
  • HOCH Health Ostschweiz - Kantonsspital St.Gallen Klinik für Dermatologie, Venerologie und Allergologie
    Sankt Gallen, 9007, Switzerland
    Recruiting
  • PLAZA Kliniken
    Uster, 8610, Switzerland
    Recruiting
    • Tobias Plaza, Dr. med. · Contactt.plaza@hin.ch · +41 44 940 49 49
  • Institut für Dermatologie und Venerologie Stadtspital Zürich Europaallee
    Zurich, Switzerland
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for May 2032, 119 months after the start.

Of 97 non-industry observational studies under Dermatitis, Atopic, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 19. This study's planned 119 months is above that.

Counting every sponsor, half of 171 studies reached it within 35 months; a quarter within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2023
First posted
Apr 19, 2023
StartActual
Jun 2, 2022
Primary completionEst.
May 2032
CompletionEst.
Dec 31, 2032
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 3 sites removed
Show 4 added (4 Switzerland)
  • Dermatologie et vénéréologie, Hôpitaux Universitaires de Genève (HUG) · Geneva, Switzerland
  • Luzerner Kantonsspital, Zentrum für Dermatologie und Allergologie · Lucerne, Switzerland
  • HOCH Health Ostschweiz - Kantonsspital St.Gallen Klinik für Dermatologie, Venerologie und Allergologie · Sankt Gallen, Switzerland
  • Institut für Dermatologie und Venerologie Stadtspital Zürich Europaallee · Zurich, Switzerland
Show 3 removed
  • Luzerner Kantonsspital, Zentrum für Dermatologie und Allergologie · Luzern, Switzerland
  • Kantonsspital St. Gallen - Klinik für Dermatologie, Venerologie und Allergologie · St. Gallen, Switzerland
  • Institut für Dermatologie und Venerologie Stadtspital Zürich Europaallee · Zürich, Switzerland
Nov 17, 2026
Eligibility
1 inclusion criterion added
What changed in the criteria
Inclusion criteria
  • Addedcurrent or anti-inflammatory topical therapy with JAK inhibitors
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    4 sites added, 3 sites removed
    Show 4 added (4 Switzerland)
    • Dermatologie et vénéréologie, Hôpitaux Universitaires de Genève (HUG) · Geneva, Switzerland
    • Luzerner Kantonsspital, Zentrum für Dermatologie und Allergologie · Lucerne, Switzerland
    • HOCH Health Ostschweiz - Kantonsspital St.Gallen Klinik für Dermatologie, Venerologie und Allergologie · Sankt Gallen, Switzerland
    • Institut für Dermatologie und Venerologie Stadtspital Zürich Europaallee · Zurich, Switzerland
    Show 3 removed
    • Luzerner Kantonsspital, Zentrum für Dermatologie und Allergologie · Luzern, Switzerland
    • Kantonsspital St. Gallen - Klinik für Dermatologie, Venerologie und Allergologie · St. Gallen, Switzerland
    • Institut für Dermatologie und Venerologie Stadtspital Zürich Europaallee · Zürich, Switzerland
    Eligibility 1 inclusion criterion added
    What changed in the criteria
    Inclusion criteria
    • Addedcurrent or anti-inflammatory topical therapy with JAK inhibitors
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05819463
Lead sponsor
Swiss Society of Dermatology and Venereology
Responsible party
Sponsor
First posted
Apr 19, 2023
Start date
Jun 2, 2022
Primary completion
May 2032 (estimated)
Completion
Dec 31, 2032 (estimated)
Last update
Nov 17, 2026

Study contacts

Dagmar Simon, Prof. Dr. med.
Contact
dagmar.simon@insel.ch
+41 31 632 22 78
Dagmar Simon, Prof. Dr. med.
principal investigator · Department of Dermatology, Inselspital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion